Abstract: Activation of peroxisome proliferator-activated receptor (PPAR) α disrupts growth-related activities in a variety of human cancers. This study was designed to determine whether fenofibrate, a PPARα agonist, can suppress 4-nitroquinoline 1-oxide (4-NQO)-induced proliferative lesions in the lung of obese hyperlipidemic mice. Male Tsumura Suzuki Obese Diabetic mice were subcutaneously injected with 4-NQO to induce lung proliferative lesions, including adenocarcinomas. They were then fed a diet containing 0.01 % or 0.05 % fenofibrate for 29 weeks, starting 1 week after 4-NQO administration. At week 30, the incidence and multiplicity (number of lesions/mouse) of pulmonary proliferative lesions were lower in mice treated with 4-NQO and ...
Peroxisome proliferator-activated receptor (PPAR)-a, a lipid-sensing transcriptional factor, serves ...
Fenofibrate is a widely used anti-hyperlipidemic agonist of peroxisome proliferator-activated recept...
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome p...
Activation of peroxisome proliferator-activated receptor (PPAR) α disrupts growth-related activities...
AbstractThe excessive use of areca nut and/or tobacco may induce the production of free radicals and...
Peroxisome proliferator-activated receptor α (PPARα) is a member of the ligand-activated nuclear rec...
Obesity is characterized by lipid accumulation in distinct organs. Presently, fenofibrate is a commo...
Fenofibrate (FBR), an oral medication used to treat dyslipidemia, is a ligand of the peroxisome prol...
Peroxisome proliferator-activated receptor alpha (PPAR alpha) is a member of the ligand-activated nu...
The peroxisome proliferator-activated receptor alpha (PPAR alpha) activator fenofibrate efficiently ...
The peroxisome proliferator-activated receptor alpha (PPARα) activator fenofibrate efficiently decre...
Peroxisome proliferator-activated receptor (PPAR)-α, a lipid-sensing transcriptional factor, serves ...
Peroxisome proliferator-activated receptor α (PPARα) is a therapeutic target for hyperli...
Background: There are a lot of unmet needs in patients with triple-negative breast cancer (TNBC). Fe...
Hypertriglyceridemia is an important risk factor associated with insulin resistance and β-cell dysfu...
Peroxisome proliferator-activated receptor (PPAR)-a, a lipid-sensing transcriptional factor, serves ...
Fenofibrate is a widely used anti-hyperlipidemic agonist of peroxisome proliferator-activated recept...
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome p...
Activation of peroxisome proliferator-activated receptor (PPAR) α disrupts growth-related activities...
AbstractThe excessive use of areca nut and/or tobacco may induce the production of free radicals and...
Peroxisome proliferator-activated receptor α (PPARα) is a member of the ligand-activated nuclear rec...
Obesity is characterized by lipid accumulation in distinct organs. Presently, fenofibrate is a commo...
Fenofibrate (FBR), an oral medication used to treat dyslipidemia, is a ligand of the peroxisome prol...
Peroxisome proliferator-activated receptor alpha (PPAR alpha) is a member of the ligand-activated nu...
The peroxisome proliferator-activated receptor alpha (PPAR alpha) activator fenofibrate efficiently ...
The peroxisome proliferator-activated receptor alpha (PPARα) activator fenofibrate efficiently decre...
Peroxisome proliferator-activated receptor (PPAR)-α, a lipid-sensing transcriptional factor, serves ...
Peroxisome proliferator-activated receptor α (PPARα) is a therapeutic target for hyperli...
Background: There are a lot of unmet needs in patients with triple-negative breast cancer (TNBC). Fe...
Hypertriglyceridemia is an important risk factor associated with insulin resistance and β-cell dysfu...
Peroxisome proliferator-activated receptor (PPAR)-a, a lipid-sensing transcriptional factor, serves ...
Fenofibrate is a widely used anti-hyperlipidemic agonist of peroxisome proliferator-activated recept...
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome p...